Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | CPN1 | P15169 | 1/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.43 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.35 |
| ▸ | TPSD1 | Q9BZJ3 | 3/20 | 0.35 |
| ▸ | TPSG1 | Q9NRR2 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6275890 | 0.86 | — | — | |
| SCHEMBL29845699 | 0.77 | F2 (0.52) | F2CPN1CPB2TPSAB1TPSD1 | |
| SCHEMBL2527566 | 0.77 | F2 (0.52) | F2CPN1CPB2TPSAB1TPSD1 | |
| SCHEMBL3319860 | 0.77 | F2 (0.52) | F2CPN1CPB2TPSAB1TPSD1 | |
| SCHEMBL9059677 | 0.77 | F2 (0.52) | F2CPN1CPB2TPSAB1TPSD1 | |
| SCHEMBL10316000 | 0.76 | F2 (0.58) | F2CPN1CPB2TPSAB1TPSD1 | |
| SCHEMBL2377379 | 0.75 | KDM1A (0.35) | CPN1CPB2GAA | |
| SCHEMBL3895895 | 0.75 | CPN1 (0.42) | CPN1CPB2 | |
| SCHEMBL349335 | 0.75 | F2 (0.50) | F2CPN1CPB2GAA | |
| SCHEMBL9061263 | 0.75 | F2 (0.50) | F2CPN1CPB2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5776937-A | Adhesion receptor antagonists | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1998-07-07 | — | — | US | claimed |
| US-5627197-A | Adhesion receptor antagonists | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1997-05-06 | — | — | US | claimed |
| EP-2275433-B1 | METASTIN DERIVATIVE AND USE THEREOF | UNIV KYOTO (JP) | 2017-06-07 | — | — | EP | disclosed |
| US-8778871-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-15 | — | — | US | disclosed |
| US-8592379-B2 | Metastin derivative and use thereof | KYOTO UNIVERSITY (JP) | 2013-11-26 | — | — | US | disclosed |
| US-8361968-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-29 | — | — | US | disclosed |
| US-20120015868-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20110039786-A1 | METASTIN DERIVATIVE AND USE THEREOF | KYOTO UNIVERSITY (JP) | 2011-02-17 | — | — | US | disclosed |
| EP-2275433-A1 | METASTIN DERIVATIVE AND USE THEREOF | Kyoto University (JP) | 2011-01-19 | — | — | EP | disclosed |
| US-7786083-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-31 | — | — | US | disclosed |
| US-20090318365-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
| US-6204280-B1 | OXAZOLIDINONE DERIVATIVE, ANTICOAGULANT | MERCK PATENT GESELLSCHAFT MIT BERSCHRANKTER HAFTUNG (DE) | 2001-03-20 | — | — | US | disclosed |
| WO-2000075172-A2 | FACTOR VIIa INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-12-14 | — | — | WO | disclosed |
| EP-1059302-A1 | Factor VIIa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2000-12-13 | — | — | EP | disclosed |
| EP-0710657-B1 | Antagonists of adhesion receptors | MERCK PATENT GMBH (DE) | 1998-08-26 | — | — | EP | disclosed |
| US-5776937-A | Adhesion receptor antagonists | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1998-07-07 | — | — | US | disclosed |
| US-5627197-A | Adhesion receptor antagonists | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1997-05-06 | — | — | US | disclosed |
| EP-0727425-A1 | Adhesion receptor antagonists | MERCK PATENT GmbH (DE) | 1996-08-21 | — | — | EP | disclosed |
| EP-0711770-A1 | Antagonists of adhesion receptors | MERCK PATENT GmbH (DE) | 1996-05-15 | — | — | EP | disclosed |
| EP-0710657-A1 | Antagonists of adhesion receptors | MERCK PATENT GmbH (DE) | 1996-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015868-A1 | Metastin derivatives and use thereof | MET, HGFAC, HGF | F2 546/4885CPN1 610/4885CPB2 215/4885 |
| US-20090318365-A1 | METASTIN DERIVATIVES AND USE THEREOF | MET, HGF, HGFAC | F2 593/4885CPN1 707/4885CPB2 246/4885 |
| US-20110039786-A1 | METASTIN DERIVATIVE AND USE THEREOF | MEN1, HGF, STMN1 | F2 1170/4885CPN1 2539/4885CPB2 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.